Quest Diagnostics Incorporated (NYSE:DGX), a prominent provider of diagnostic testing and information services, has hit a record-breaking share price of $180.11, pushing the company’s market capitalization to nearly $20 billion. Analysts currently view the stock as trading above its estimated fair value, signaling robust investor confidence.

The achievement follows a year of steady growth, during which Quest delivered a total return of 31.86% and maintained low stock price volatility. The company has consistently rewarded shareholders, sustaining dividend payments for 22 consecutive years with a current yield of 1.79%.

The new all-time high coincides with a strong Q1 2025 earnings report. Quest reported adjusted earnings per share of $2.21, outpacing analyst projections of $2.16. Revenue also topped expectations, coming in at $2.65 billion—a 12.1% increase year-over-year.

This financial strength led Fitch Ratings to upgrade the company’s Long-Term Issuer Default Rating to ‘BBB+’ with a stable outlook, citing consistent operational results and disciplined growth. In response, JPMorgan raised its price target from $180 to $190 and adjusted EPS forecasts for 2025 and 2026 while maintaining a Neutral rating.

At the company’s 2025 Annual Meeting, shareholders voted to approve executive compensation plans and re-elected directors. They also ratified the appointment of PricewaterhouseCoopers as the company’s independent auditor for the fiscal year. A proposal to allow shareholders to call special meetings did not pass.

Overall, Quest’s performance reflects strong market positioning and investor trust in its strategic trajectory and financial stewardship.

Quest Diagnostics stock price